Biobanking of Salivary Gland Tumours: Insights from the Polish Salivary Gland Network Towards Future Digital Integration and Image-Based Research

<b>Introduction:</b> Salivary gland tumours (SGTs) remain poorly represented in large-scale research due to low incidence and anatomical heterogeneity. Biobanking and data integration for SGTs remain particularly limited, as these tumours are often excluded from malignant tumour registries; even when data are collected centrally, they frequently lack sufficient detail and standardization, hindering harmonization and meaningful analysis.<b>Aim:</b> To present the design and early implementation of the Polish Salivary Gland Network (PSGN), a multicentre initiative linking standardized clinical data with ISO 20387-compliant biobanking infrastructure for SGTs.<b>Materials and methods:</b> The PSGN collects harmonized clinical, surgical, and pathological data from eight academic university departments across Poland (2017-2025). The data are managed using NorayBanks software, ensuring full traceability, regulatory compliance, and standardized data governance. This infrastructure lays the foundation for future digital integration, image-based research, and AI-supported analyses. Additional efforts focus on data quality assurance, process mapping, and dataset harmonization to enable multicentre interoperability and research scalability.<b>Results:</b> As of 2025, the PSGN holds data on 3,654 patients with SGT (mean age: 58.3 years; 62% female), including >70 clinicopathological variables per case. While parotid tumours dominate, ~3.7% involve rare sites such as the parapharyngeal space. The registry includes treatment details and key outcomes such as DFS, OS, and recurrence. Early findings suggest potential to inform clinical decision-making and uncover diagnostic challenges.<b>Conclusions:</b> The PSGN is the first structured platform for SGT biobanking. It provides a foundation for data-driven research and sets the stage for future digital and molecular advancements in rare cancer studies.